Top

BMC Cancer

Published in:

Open Access 01-12-2019 | Lung Cancer | Research article

Distinct signatures of lung cancer types: aberrant mucin O-glycosylation and compromised immune response

Authors: Marta Lucchetta, Isabelle da Piedade, Mohamed Mounir, Marina Vabistsevits, Thilde Terkelsen, Elena Papaleo

Published in: BMC Cancer | Issue 1/2019

Abstract

Background

Genomic initiatives such as The Cancer Genome Atlas (TCGA) contain data from -omics profiling of thousands of tumor samples, which may be used to decipher cancer signaling, and related alterations. Managing and analyzing data from large-scale projects, such as TCGA, is a demanding task. It is difficult to dissect the high complexity hidden in genomic data and to account for inter-tumor heterogeneity adequately.

Methods

In this study, we used a robust statistical framework along with the integration of diverse bioinformatic tools to analyze next-generation sequencing data from more than 1000 patients from two different lung cancer subtypes, i.e., the lung adenocarcinoma (LUAD) and the squamous cell carcinoma (LUSC).

Results

We used the gene expression data to identify co-expression modules and differentially expressed genes to discriminate between LUAD and LUSC. We identified a group of genes which could act as specific oncogenes or tumor suppressor genes in one of the two lung cancer types, along with two dual role genes. Our results have been validated against other transcriptomics data of lung cancer patients.

Conclusions

Our integrative approach allowed us to identify two key features: a substantial up-regulation of genes involved in O-glycosylation of mucins in LUAD, and a compromised immune response in LUSC. The immune-profile associated with LUSC might be linked to the activation of three oncogenic pathways, which promote the evasion of the antitumor immune response. Collectively, our results provide new future directions for the design of target therapies in lung cancer.

Available only for authorised users

Travis WD, Brambilla E, Nicholson AG, Yatabe Y, Austin JHM, Beasley MB, et al. The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances since the 2004 Classification. J Thorac Oncol. 2015;10:1243–60. Available from:. https://doi.org/10.1097/JTO.0000000000000630.PubMedCrossRef

Kadota K, Sima CS, Arcila ME, Hedvat C, Mark KG, Jones DR, et al. KRAS mutation is a significant prognostic factor in early stage lung adenocarcinoma. Am J Surg Pathol. 2016;40:1579–90.PubMedPubMedCentralCrossRef

Chen Z, Fillmore CM, Hammerman PS, Kim CF, Wong K-K. Non-small-cell lung cancers: a heterogeneous set of diseases. Nat rev Cancer. Nat Publ Group. 2014;14:535–46. Available from:. https://doi.org/10.1038/nrc3775.CrossRef

Kadota K, Yeh Y-C, D’Angelo SP, Moreira AL, Kuk D, Sima CS, et al. Associations between mutations and histologic patterns of mucin in lung adenocarcinoma: invasive mucinous pattern and extracellular mucin are associated with KRAS mutation. Am J Surg Pathol. 2014;38:1118–27.PubMedPubMedCentralCrossRef

Shea M, Costa DB, Rangachari D. Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches. Ther Adv Respir Dis. 2016;10:113–29.PubMedCrossRef

Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, et al. Paclitaxel–carboplatin alone or with bevacizumab for non–small-cell lung Cancer. N Engl J Med. 2006;355:2542–50. Available from:. https://doi.org/10.1056/NEJMoa061884.PubMedCrossRef

Gordon GJ, Jensen RV, Hsiao LL, Gullans SR, Blumenstock JE, Ramaswamy S, et al. Translation of microarray data into clinically relevant cancer diagnostic tests using gene expression ratios in lung cancer and mesothelioma. Cancer Res. 2002;62:4963–7.PubMed

Sanchez-Palencia A, Gomez-Morales M, Gomez-Capilla JA, Pedraza V, Boyero L, Rosell R, et al. Gene expression profiling reveals novel biomarkers in nonsmall cell lung cancer. Int J Cancer. 2011;129:355–64.PubMedCrossRef

Navab R, Strumpf D, Bandarchi B, Zhu C, Pintilie M, Rohan V. Prognostic gene-expression signature of carcinoma- associated fibroblasts in non-small cell lung cancer. Proc Natl Acad Sci U S A. 2011;108:7160–5.PubMedPubMedCentralCrossRef

10.

Girard L, Rodriguez-Canales J, Behrens C, Thompson DM, Botros IW, Tang H, et al. An expression signature as an aid to the histologic classification of non-small cell lung cancer. Clin Cancer Res. 2016;22:4880–9.PubMedPubMedCentralCrossRef

11.

Cui R, Meng W, Sun H-L, Kim T, Ye Z, Fassan M, et al. MicroRNA-224 promotes tumor progression in nonsmall cell lung cancer. Proc Natl Acad Sci U S A. 2015:E4288–97. Available from:. https://doi.org/10.1073/pnas.1502068112.CrossRef

12.

Raponi M, Zhang Y, Yu J, Chen G, Lee G, Taylor JMG, et al. Gene expression signatures for predicting prognosis of squamous cell and adenocarcinomas of the lung. Cancer Res. 2006;66:7466–72.PubMedCrossRef

13.

Hamamoto J, Soejima K, Yoda S, Naoki K, Nakayama S, Satomi R, et al. Identification of microRNAs differentially expressed between lung squamous cell carcinoma and lung adenocarcinoma. Mol Med Rep. 2013;8:456–62.PubMedCrossRef

14.

Liu J, Yang XY, Shi WJ. Identifying differentially expressed genes and pathways in two types of non-small cell lung cancer: adenocarcinoma and squamous cell carcinoma. Genet Mol Res. 2014;13:95–102 Available from: http://www.ncbi.nlm.nih.gov/pubmed/24446291.PubMedCrossRef

15.

Russo PST, Ferreira GR, Cardozo LE, Bürger MC, Arias-Carrasco R, Maruyama SR, et al. CEMiTool: a Bioconductor package for performing comprehensive modular co-expression analyses. BMC Bioinformatics. 2018;19:1–13.CrossRef

16.

Langfelder P, Horvath S. WGCNA: an R package for weighted correlation network analysis. BMC Bioinformatics. 2008;9:559.

17.

Gonzalez-Valbuena E-E, Treviño V. Metrics to estimate differential co- expression networks. BioData Min. 2017;10:32.

18.

Wolf DM, Lenburg ME, Yau C, Boudreau A, Van’t Veer LJ. Gene co-expression modules as clinically relevant hallmarks of breast cancer diversity. PLoS One. 2014;9:e88309.PubMedPubMedCentralCrossRef

19.

Gov E, Arga KY. Differential co-expression analysis reveals a novel prognostic gene module in ovarian cancer. Sci Rep. 2017;7:1–10.CrossRef

20.

Wang W, Hu B, Wang X, Chen J, Qian X, He Y. Candidate genes in gastric cancer identified by constructing a weighted gene co-expression network. PeerJ. 2018;6:e4692.PubMedPubMedCentralCrossRef

21.

Shi Z, Derow CK, Zhang B. Co-expression module analysis reveals biological processes, genomic gain, and regulatory mechanisms associated with breast cancer progression. BMC Syst Biol. 2010;4:74.PubMedPubMedCentralCrossRef

22.

Han L, Hei N, Li J, Yuan Y, Liang H, Yang Y. Gene co-expression network analysis reveals common system-level properties of prognostic genes across cancer types. Nat Commun [internet]. Nat Publ Group. 2014;5:1–9. Available from:. https://doi.org/10.1038/ncomms4231.CrossRef

23.

Federoff HJ, Meehan RR, Villoslada P, Baranzini S, Chung KF, Sterk PJ, et al. Modules, networks and systems medicine for understanding disease and aiding diagnosis. Genome Med. 2014;6:1–11.CrossRef

24.

Belling K, Rajpert-De Meyts E, Dalgaard MD, Jensen AB, Skakkebæk NE, Brunak S, et al. Klinefelter syndrome comorbidities linked to increased X chromosome gene dosage and altered protein interactome activity. Hum Mol Genet. 2017;26:1219–29.PubMedPubMedCentralCrossRef

25.

Chang K, Creighton CJ, Davis C, Donehower L, Drummond J, Wheeler D, et al. The Cancer genome Atlas pan-Cancer analysis project. Nat Genet. 2013;45:1113–20 Available from: http://www.ncbi.nlm.nih.gov/pubmed/24071849.CrossRef

26.

Tomczak K, Czerwińska P, Wiznerowicz M. The Cancer genome Atlas (TCGA): an immeasurable source of knowledge. Wspolczesna Onkol. 2015;1A:A68–77.CrossRef

27.

Tian F, Zhao J, Fan X, Kang Z. Weighted gene co-expression network analysis in identification of metastasis-related genes of lung squamous cell carcinoma based on the Cancer genome Atlas database. J Thorac Dis. 2017;9:42–53.PubMedPubMedCentralCrossRef

28.

Wang Z, Gerstein M, Snyder M. RNA-Seq: a revolutionary tool for transcriptomics. Nat Rev Genet. 2009;10:57–63 Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2949280&tool=pmcentrez&rendertype=abstract.PubMedPubMedCentralCrossRef

29.

Cancer T, Atlas G, Collisson EA, Campbell JD, Brooks AN, Berger AH, et al. Comprehensive molecular profiling of lung adenocarcinoma. Nature. 2014;511:543–50 Available from: http://www.nature.com/doifinder/10.1038/nature13385%5Cnhttp://www.ncbi.nlm.nih.gov/pubmed/25079552%5Cn/link?doi=10.1038/nature13385.CrossRef

30.

Hammerman PS, Lawrence MS, Voet D, Jing R, Cibulskis K, Sivachenko A, et al. Comprehensive genomic characterization of squamous cell lung cancers. Nature. 2012;489:519–25 Available from: http://www.nature.com/doifinder/10.1038/nature11404.CrossRef

31.

Collado-Torres L, Nellore A, Kammers K, Ellis SE, Taub MA, Hansen KD, et al. Reproducible RNA-seq analysis using recount2. Nat Biotechnol. 2017;35:319–21.PubMedPubMedCentralCrossRef

32.

Carithers LJ, Moore HM. The genotype-tissue expression (GTEx) project. Biopreserv Biobank. 2015;13:307–8. Available from. https://doi.org/10.1089/bio.2015.29031.hmm.PubMedPubMedCentralCrossRef

33.

Kandoth C, McLellan MD, Vandin F, Ye K, Niu B, Lu C, et al. Mutational landscape and significance across 12 major cancer types. Nature [internet]. Nat Publ Group. 2013;502:333–9 Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3927368&tool=pmcentrez&rendertype=abstract.

34.

Goldman M, Craft B, Swatloski T, Ellrott K, Cline M, Diekhans M, et al. The UCSC cancer genomics browser: update 2013. Nucleic Acids Res. 2013;41:951–9.CrossRef

35.

Hoadley KA, Yau C, Wolf DM, Cherniack AD, Tamborero D, Ng S, et al. Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin. Cell. 2014;158:929–44. Available from:. https://doi.org/10.1016/j.cell.2014.06.049.PubMedPubMedCentralCrossRef

36.

Jia P, Pao W, Zhao Z. Patterns and processes of somatic mutations in nine major cancers. BMC Med Genomics. 2014;7:11 Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3942057&tool=pmcentrez&rendertype=abstract.PubMedPubMedCentralCrossRef

37.

Colaprico A, Olsen C, Cava C, Terkelsen T, Silva TC, Olsen A, et al. Moonlight: a tool for biological interpretation and driver genes discovery. bioarXiv. 2018. Article number: 265322. https://doi.org/10.1101/265322.

38.

Rahman M, Jackson LK, Johnson WE, Li DY, Bild AH, Piccolo SR. Alternative preprocessing of RNA-sequencing data in the Cancer genome Atlas leads to improved analysis results. Bioinformatics. 2015;31:3666–72.PubMedPubMedCentralCrossRef

39.

Cline MS, Craft B, Swatloski T, Goldman M, Ma S, Haussler D, et al. Exploring TCGA Pan-Cancer data at the UCSC Cancer Genomics Browser. Sci Rep. 2013;3:2652 Available from: http://www.nature.com/srep/2013/131002/srep02652/full/srep02652.html.PubMedPubMedCentralCrossRef

40.

Huang Q, Wei H, Wu Z, Li L, Yao L. Preferentially expressed antigen of melanoma prevents lung Cancer metastasis. PLoS One. 2016;11:1–15.

41.

Hammerman PS, Sos ML, Ramos AH, Xu C, Dutt A, Zhou W, et al. Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. Cancer Discov. 2012;1:78–89.CrossRef

42.

Capizzi M, Strappazzon F, Cianfanelli V. MIR7-3HG , a MYC-dependent modulator of cell proliferation , inhibits autophagy by a regulatory loop involving AMBRA1. Autophagy. 2017;1:1–41. Available from:. https://doi.org/10.1080/15548627.2016.1269989.CrossRef

43.

Colaprico A, Silva TC, Olsen C, Garofano L, Cava C, Garolini D, et al. TCGAbiolinks: an R/Bioconductor package for integrative analysis of TCGA data. Nucleic Acids Res. 2015;44:gkv1507 Available from: http://nar.oxfordjournals.org/content/early/2015/12/23/nar.gkv1507.full.

44.

Silva TC, Colaprico A, Olsen C, D’Angelo F, Bontempi G, Ceccarelli M, et al. TCGA Workflow: Analyze cancer genomics and epigenomics data using Bioconductor packages. F1000Res. 2016;5:1542 Available from: http://f1000research.com/articles/5-1542/v1.PubMedPubMedCentralCrossRef

45.

Aran D, Sirota M, Butte AJ. Systematic pan-cancer analysis of tumour purity. Nat Commun. 2015;6:8971 Available from: http://www.ncbi.nlm.nih.gov/pubmed/26634437.PubMedCrossRef

46.

Huber W, Carey VJ, Gentleman R, Anders S, Carlson M, Carvalho BS, et al. Orchestrating high-throughput genomic analysis with Bioconductor. Nat Methods. 2015;12:115–21.PubMedPubMedCentralCrossRef

47.

Risso D, Ngai J, Speed TP, Dudoit S. Normalization of RNA-seq data using factor analysis of control genes or samples. Nat Biotechnol. 2014;32:896–902. Available from:. https://doi.org/10.1038/nbt.2931.PubMedPubMedCentralCrossRef

48.

Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics. 2009;26:139–40.PubMedPubMedCentralCrossRef

49.

Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, et al. Limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43:e47.PubMedPubMedCentralCrossRef

50.

Lex A, Gehlenborg N, Strobelt H. UpSet : visualization of intersecting sets. IEEE Trans Vis Comput Graph. 2014;20:1983–92.PubMedPubMedCentralCrossRef

51.

Mounir M, Lucchetta M, Silva TC, Olsen C, Bontempi G, Chen X, et al. New functionalities in the TCGAbiolinks package for the study and integration of cancer data from GDC and GTEx. PLOS Comput Biol. 2019;15:e1006701 Available from: http://dx.plos.org/10.1371/journal.pcbi.1006701.PubMedPubMedCentralCrossRef

52.

Zhang J, Haider S, Baran J, Cros A, Guberman JM, Hsu J, et al. BioMart: a data federation framework for large collaborative projects. Database. 2011;2011:1–15.

53.

Durinck S, Moreau Y, Kasprzyk A, Davis S, De Moor B, Brazma A, et al. BioMart and Bioconductor: a powerful link between biological databases and microarray data analysis. Bioinformatics. 2005;21:3439–40.PubMedCrossRef

54.

Durinck S, Spellman PT, Birney E, Huber W. Mapping identifiers for the integration of genomic datasets with the R/Bioconductor package biomaRt. Nat Protoc. 2009;4:1184–91.PubMedPubMedCentralCrossRef

55.

Kumar L, Futschik ME. Mfuzz: a software package for soft clustering of microarray data. Bioinformation. 2007;2:5–7 Available from: http://www.bioinformation.net/002/000200022007.htm.PubMedPubMedCentralCrossRef

56.

Futschik ME, Carlisle B. Noise-robust soft clustering of gene expression time-course data. J Bioinform Comput Biol. 2005;03:965–88. Available from:. https://doi.org/10.1142/S0219720005001375.CrossRef

57.

Guangchuang Y, Qing-Yu H. ReactomePA: an R/Bioconductor package for reactome pathway analysis and visualization. Mol BioSyst. 2016;12:477–9.CrossRef

58.

Yu G, Wang L-G, Han Y, He Q-Y. clusterProfiler: an R Package for Comparing Biological Themes Among Gene Clusters. Omi A J Integr Biol. 2012;16:284–7. Available from:. https://doi.org/10.1089/omi.2011.0118.CrossRef

59.

Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, et al. Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet. 2000;25:25–9. Available from:. https://doi.org/10.1038/75556.PubMedPubMedCentralCrossRef

60.

Walter W, Sánchez-Cabo F, Ricote M. GOplot: an R package for visually combining expression data with functional analysis. Bioinformatics. 2015;31:2912–4.PubMedCrossRef

61.

Kotlyar M, Pastrello C, Sheahan N, Jurisica I. Integrated interactions database: tissue-specific view of the human and model organism interactomes. Nucleic Acids Res. 2016;44:D536–41 Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4702811&tool=pmcentrez&rendertype=abstract.PubMedCrossRef

62.

Christensen E. Multivariate survival analysis using Cox’s regression model. Hepatology. 1987;7:1346–58 Available from: http://www.ncbi.nlm.nih.gov/pubmed/3679094.PubMedCrossRef

63.

Benjamini Y, Hochberg Y. Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. J Royal Stat Soc Ser B. 1995;57:289–300 Available from: https://www.jstor.org/stable/2346101.

64.

Bhattacharjee A, Richards WG, Staunton J, Li C, Monti S, Vasa P, et al. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci U S A. 2001;98:13790–5. Available from:. https://doi.org/10.1073/pnas.191502998.PubMedPubMedCentralCrossRef

65.

Meister M, Belousov A, Xu E, Schnabel P, Warth A, Hoofmann H, et al. Intra-tumor heterogeneity of gene expression profiles in early stage non-small cell lung cancer. J Bioinforma Res Stud. 2014;1:1.

66.

Reimand J, Arak T, Adler P, Kolberg L, Reisberg S, Peterson H, et al. g:Profiler—a web server for functional interpretation of gene lists (2016 update). Nucleic Acids Res. 2016;44:W83-89 Available from: http://nar.oxfordjournals.org/content/early/2016/04/29/nar.gkw199.abstract.PubMedPubMedCentralCrossRef

67.

Becht E, Giraldo NA, Lacroix L, Buttard B, Elarouci N, Petitprez F, et al. Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression. Genome Biol. 2016;17:218 Available from: http://www.ncbi.nlm.nih.gov/pubmed/27765066.PubMedPubMedCentralCrossRef

68.

Soneson C, Delorenzi M. A comparison of methods for differential expression analysis of RNA-seq data. BMC Bioinformatics. 2013;14:91 Available from: http://www.biomedcentral.com/1471-2105/14/91.PubMedPubMedCentralCrossRef

69.

Germain P-L, Vitriolo A, Adamo A, Laise P, Das V, Testa G. RNAontheBENCH: computational and empirical resources for benchmarking RNAseq quantification and differential expression methods. Nucleic Acids Res. 2016;44(11):5054–67. Available from:. https://doi.org/10.1093/nar/gkw448.PubMedPubMedCentralCrossRef

70.

Finotello F, Di Camillo B. Measuring differential gene expression with RNA-seq: challenges and strategies for data analysis. Brief Funct Genomics. 2015;14:130–42.PubMedCrossRef

71.

Tang M, Sun J, Shimizu K, Kadota K. Evaluation of methods for differential expression analysis on multi-group RNA-seq count data. BMC bioinformatics [internet]. BMC Bioinformatics. 2015:1–14. Available from:. https://doi.org/10.1186/s12859-015-0794-7.

72.

Kao S, Shiau CK, Gu DL, Ho CM, Su WH, Chen CF, et al. IGDB.NSCLC: Integrated genomic database of non-small cell lung cancer. Nucleic Acids Res. 2012;40:972–7.CrossRef

73.

Edge SB, Compton CC. The american joint committee on cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010;17:1471–4.PubMedCrossRef

74.

Shen L, Shi Q, Wang W. Double agents : genes with both oncogenic and tumor-suppressor functions. Oncogenesis. 2018; Available from:. https://doi.org/10.1038/s41389-018-0034-x.

75.

Zhao M, Kim P, Mitra R, Zhao J, Zhao Z. TSGene 2.0: an updated literature-based knowledgebase for tumor suppressor genes. Nucleic Acids Res. 2015;44:D0123-D1031.PubMedPubMedCentralCrossRef

76.

Liu Y, Sun J, Zhao M. ONGene: a literature-based database for human oncogenes. J Genet Genomics. 2017;44:119–21. Available from:. https://doi.org/10.1016/j.jgg.2016.12.004.PubMedCrossRef

77.

Forbes SA, Beare D, Gunasekaran P, Leung K, Bindal N, Boutselakis H, et al. COSMIC: exploring the world’s knowledge of somatic mutations in human cancer. Nucleic Acids Res. 2015;43:D805–11. Available from:. https://doi.org/10.1093/nar/gku1075.PubMedCrossRef

78.

Reis ES, Mastellos DC, Ricklin D, Mantovani A, Lambris JD. Complement in cancer: untangling an intricate relationship. Nat rev Immunol. Nat Publ Group. 2018;18:5–18. Available from:. https://doi.org/10.1038/nri.2017.97.CrossRef

79.

Espinoza JA, Jabeen S, Batra R, Papaleo E, Haakensen V, Timmermans Wielenga V, et al. Cytokine profiling of tumour interstitial fluid of the breast and its relationship with lymphocyte infiltration and clinicopathological characteristics. Oncoimmunology. 2016;5:00 Available from: https://www.tandfonline.com/doi/full/10.1080/2162402X.2016.1248015.CrossRef

80.

Su C, Zhou C, Zhou S, Xu J. Serum cytokine levels in patients with advanced non-small cell lung cancer: correlation with treatment response and survival. Med Oncol. 2011;28:1453–7.PubMedCrossRef

81.

Han H, Cho J-W, Lee S, Yun A, Kim H, Bae D, et al. TRRUST v2: an expanded reference database of human and mouse transcriptional regulatory interactions. Nucleic Acids Res. 2018;46:D380–6 Available from: http://academic.oup.com/nar/article/46/D1/D380/4566018.PubMedCrossRef

82.

Pletscher-Frankild S, Pallejà A, Tsafou K, Binder JX, Jensen LJ. DISEASES: Text mining and data integration of disease-gene associations. Methods. 2015;74:83–9. Available from:. https://doi.org/10.1016/j.ymeth.2014.11.020.PubMedCrossRef

83.

Lennon FE, Salgia R, Mambetsariev N, Mirzapoiazova T, Mambetsariev B, Singleton PA, et al. HABP2 is a novel regulator of Hyaluronan-mediated human lung Cancer progression. Front Oncol. 2015;5:1–12.

84.

Williams S, Bateman A, O’Kelly I. Altered expression of two-pore domain potassium (K2P) channels in Cancer. PLoS One. 2013;8:e74589.PubMedPubMedCentralCrossRef

85.

Rivenbark AG, Coleman WB. Epigenetic regulation of cystatins in cancer. Front Biosci. 2009;14:453–62.CrossRef

86.

Tan Y, Zhang T, Zhou L, Liu S, Liang C. MiR-34b-3p Represses the Multidrug-Chemoresistance of Bladder Cancer Cells by Regulating the CCND2 and P2RY1 Genes. Med Sci Monit. 2019;25:1323–35 Available from: https://www.medscimonit.com/abstract/index/idArt/913746.PubMedPubMedCentralCrossRef

87.

Hata H, Tatemichi M, Nakadate T. Involvement of annexin A8 in the properties of pancreatic cancer. Mol Carcinog. 2012;53:181–91 Available from: https://onlinelibrary.wiley.com/doi/full/10.1002/mc.21961.PubMedCrossRef

88.

Polakis P. Wnt signaling in Cancer. Cold Spring Harb Perspect Biol. 2012;4:1–13.CrossRef

89.

King TD, Zhang W, Suto MJ, Li Y. Frizzled7 as an emerging target for cancer therapy. Cell Signal. 2012;24:846–51. Available from:. https://doi.org/10.1016/j.cellsig.2011.12.009.PubMedCrossRef

90.

Brooks DLP, Schwab LP, Krutilina R, Parke DN, Sethuraman A, Hoogewijs D, et al. ITGA6 is directly regulated by hypoxia-inducible factors and enriches for cancer stem cell activity and invasion in metastatic breast cancer models. Mol Cancer [internet]. Mol Cancer. 2016;15:1–19. Available from:. https://doi.org/10.1186/s12943-016-0510-x.CrossRef

91.

Malta TM, Sokolov A, Gentles AJ, Burzykowski T, Poisson L, Weinstein JN, et al. Machine Learning Identifies Stemness Features Associated with Oncogenic Dedifferentiation. Cell. 2018;173:338–354.e15.PubMedPubMedCentralCrossRef

92.

Gong G, Woo J, Lee J, Kim MS, Jang SJ, Kang SK, et al. Expression of aquaporin 5 (AQP5) promotes tumor invasion in human non small cell lung Cancer. PLoS One. 2008;3:e2162.PubMedPubMedCentralCrossRef

93.

Wang W, Chu H, Liang Y, Huang J, Shang C, Tan H, et al. FABP5 correlates with poor prognosis and promotes tumor cell growth and metastasis in cervical cancer. Tumor Biol. 2016;37:14873–83 Available from: http://link.springer.com/10.1007/s13277-016-5350-1.CrossRef

94.

Kawaguchi K, Senga S, Kubota C, Kawamura Y, Ke Y, Fujii H. High expression of Fatty Acid-Binding Protein 5 promotes cell growth and metastatic potential of colorectal cancer cells. FEBS Open Bio. 2016;6:190–9. Available from:. https://doi.org/10.1002/2211-5463.12031.PubMedPubMedCentralCrossRef

95.

Liu R-Z, Graham K, Glubrecht DD, Germain DR, Mackey JR, Godbout R. Association of FABP5 Expression With Poor Survival in Triple-Negative Breast Cancer: Implication for Retinoic Acid Therapy. Am J Pathol. 2011;178:997–1008 Available from: https://www.sciencedirect.com/science/article/pii/S000294401000221X.PubMedPubMedCentralCrossRef

96.

Zhuo H, Zhao Y, Cheng X, Xu M, Wang L, Lin L, et al. Tumor endothelial cell-derived cadherin-2 promotes angiogenesis and has prognostic significance for lung adenocarcinoma. Mol Cancer. 2019;18:34 Available from: https://molecular-cancer.biomedcentral.com/articles/10.1186/s12943-019-0987-1.PubMedPubMedCentralCrossRef

97.

Górka B, Skubis-Zegadło J, Mikula M, Bardadin K, Paliczka E, Czarnocka B. NrCAM, a neuronal system cell-adhesion molecule, is induced in papillary thyroid carcinomas. Br J Cancer. 2007;97:531–8 Available from: http://www.nature.com/articles/6603915.PubMedPubMedCentralCrossRef

98.

Hsu Y-L, Hung J-Y, Lee Y-L, Chen F-W, Chang K-F, Chang W-A, et al. Identification of novel gene expression signature in lung adenocarcinoma by using next-generation sequencing data and bioinformatics analysis. Oncotarget. 2017;8:104831–54 Available from: http://www.oncotarget.com/fulltext/21022.PubMedPubMedCentral

99.

Alavi M, Mah V, Maresh EL, Bagryanova L, Horvath S, Chia D, et al. High expression of AGR2 in lung cancer is predictive of poor survival. BMC Cancer. 2015;15:655 Available from: http://bmccancer.biomedcentral.com/articles/10.1186/s12885-015-1658-2.PubMedPubMedCentralCrossRef

100.

Dietel M. Article in Histology and histopathology. 2007 [cited 2019 Mar 22]; Available from: http://www.hh.um.es

101.

Hollingsworth MA, Swanson BJ. Mucins in cancer: protection and control of the cell surface. Nat Rev Cancer. 2004;4:45–60 Available from: http://www.nature.com/doifinder/10.1038/nrc1251.PubMedCrossRef

102.

Lakshmanan I, Ponnusamy MP, Macha MA, Haridas D, Majhi PD, Kaur S, et al. Mucins in lung cancer: Diagnostic, prognostic, and therapeutic implications. J Thorac Oncol. 2015;10:19–27. Available from:. https://doi.org/10.1097/JTO.0000000000000404.PubMedCrossRef

103.

Yu C-J, Shih J-Y, Lee Y-C, Shun C-T, Yuan A, Yang P-C. Sialyl Lewis antigens: association with MUC5AC protein and correlation with post-operative recurrence of non-small cell lung cancer. Lung Cancer. 2005;47:59–67 Available from: http://linkinghub.elsevier.com/retrieve/pii/S0169500204002594.PubMedCrossRef

104.

Valque H, Gouyer V, Gottrand F, Desseyn JL. MUC5B leads to aggressive behavior of breast Cancer MCF7 cells. PLoS One. 2012;7:e46699.PubMedPubMedCentralCrossRef

105.

Garcia EP, Tiscornia I, Libisch G, Trajtenberg F, Bollati-Fogolin M, Rodriguez E, et al. MUC5B silencing reduces chemo-resistance of MCF-7 breast tumor cells and impairs maturation of dendritic cells. Int J Oncol. 2016;48:2113–23.PubMedCrossRef

106.

Jonckheere N, Skrypek N, Van Seuningen I. Mucins and tumor resistance to chemotherapeutic drugs. Biochim Biophys Acta. 2014;1846:142–51. Available from:. https://doi.org/10.1016/j.bbcan.2014.04.008.PubMedCrossRef

107.

Guo L, Zhang H, Chen B. Nivolumab as programmed Death-1 (PD-1) inhibitor for targeted immunotherapy in tumor. J Cancer. 2017;8:410–6.PubMedPubMedCentralCrossRef

108.

Faruki H, Mayhew GM, Serody JS, Hayes DN, Perou CM, Lai-Goldman M. Lung adenocarcinoma and squamous cell carcinoma gene expression subtypes demonstrate significant differences in tumor immune landscape. J Thorac Oncol. 2017;12:943–53. Available from:. https://doi.org/10.1016/j.jtho.2017.03.010.PubMedPubMedCentralCrossRef

109.

Spranger S, Gajewski TF. Impact of oncogenic pathways on evasion of antitumour immune responses. Nat Rev Cancer. 2018;18:139–47. Available from:. https://doi.org/10.1038/nrc.2017.117.PubMedPubMedCentralCrossRef

Title: Distinct signatures of lung cancer types: aberrant mucin O-glycosylation and compromised immune response
Authors: Marta Lucchetta
Isabelle da Piedade
Mohamed Mounir
Marina Vabistsevits
Thilde Terkelsen
Elena Papaleo
Publication date: 01-12-2019
Publisher: BioMed Central
Keywords: Lung Cancer
Lung Cancer
Lung Cancer
Published in: BMC Cancer / Issue 1/2019
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-019-5965-x

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2019

The effect of metformin use on hypopharyngeal squamous cell carcinoma in diabetes mellitus patients

Postoperative radiotherapy is effective in improving survival of patients with stage pIII-N2 non-small-cell lung Cancer after pneumonectomy

Lapatinib sensitivity in nasopharyngeal carcinoma is modulated by SIRT2-mediated FOXO3 deacetylation

Sequential therapeutic targeting of ovarian Cancer harboring dysfunctional BRCA1

How many samples are needed to infer truly clonal mutations from heterogenous tumours?

A phase II randomized placebo-controlled double-blind study of salvage radiation therapy plus placebo versus SRT plus enzalutamide with high-risk PSA-recurrent prostate cancer after radical prostatectomy (SALV-ENZA)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer